TLR4 and neoplasm: An important class of molecules in the preclinical and clinical development phases as vaccine adjuvants and tumour immunotherapeutics are compounds that stimulate the innate immunity receptor TLR4 (toll-like receptor 4), thus mimicking the action of endotoxin, namely, lipopolysaccharide (LPS), the natural TLR4 agonist.